A Clinical research study in pediatric patients with Rett Syndrome

Summary

This study is for female child, aged ≥ 5 to 17 years with a clinical diagnosis of Rett Syndrome to take part in a 12-week treatment clinical research study. The primary purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication for Rett Syndrome.

Individuals will be evaluated to determine their eligibility to participate in this study. Each patient who qualifies will receive either the investigational medication(ANAVEX2-73) or a placebo, as well as study-related medical exams and study-related laboratory tests, at no cost. Compensation for time and travel may also be available.

Eligibility

Currently recruiting participants: Yes

Eligible gender: Female

Eligible ages: 5 to 17

Inclusion criteria:

You or your child may be eligible to participate in this trial if you or your child:
- Female, aged ≥ 5 to 17 years
- have been diagnosed with Rett Syndrome
Doctors will also evaluate other criteria to make sure you or your child qualify for the study.

Exclusion criteria:

You or your child may not be eligible to participate in this trial if you or your child:
- have hypersensitivity to study drug
- history of liver and kidney disfunction
Doctors will also evaluate other criteria to make sure you or your child qualify for the study.

Participate

Fill out the following form if you want to participate in this research

Method of contact

Collection of personal information
Your personal information is collected under the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If you have any questions about the collection or use of this information, please visit our Access to Information page.

Additional information

Contact information

Please contact Dr. Julia Jacobs-LeVan at 4039552480 or Julia.Jacobs-LeVan@albertahealthservices.ca or study coordinator Paola Meza Santoscoy at paola.mezasantoscoy@ucalgary.ca or (587)7036623 if you would like to learn more about this trial.

Principal investigator:

Julia Jacobs-Levan

Clinical trial:

Yes

REB-ID:

REB21-1111